Peer-influenced content. Sources you trust. No registration required. This is HCN.
ACP Internist
In a study of nearly 100,000 individuals aged 30 to 95 without any prior evidence of CVD, decline in peak metabolic equivalent of task score (METS) of greater than 1.0 was inversely proportionate to changes in mortality risk. METS were determined using symptom-limited exercise treadmill tests.
Cardiology April 5th 2023
JAMA Network
A double-blind, placebo-controlled randomized clinical trial including people with COPD and chronic breathlessness was conducted at 20 Australian medical centers. One-hundred sixty participants were randomized to oral extended-release morphine versus placebo. The change in the intensity of worst breathlessness at week 1 was not significantly different between the morphine group and the placebo group.
Internal Medicine December 7th 2022
MedPage Today
Although the panel voted 16:1 for the new budesonide + albuterol inhaler in adults, they said the data does not support use in children and they were split on use in adolescents over the age of 12.
Allergy & Immunology November 29th 2022
Anakinra (Kineret, Sobi) currently approved for rheumatoid arthritis and some rare disorders, was granted an emergency use authorization for a subgroup of COVID-hospitalized patients who are at risk of severe respiratory failure.
Family Medicine/General Practice November 29th 2022
An observational analysis reviewed 54 studies and two medical record databases with data for 1.2 million individuals, to determine how many people experienced at least 1 of the 3 self-reported Long COVID symptom clusters 3 months after infection. The results indicate a Long COVID rate of 6.2%: 3.7% for ongoing respiratory problems, 3.2% for persistent fatigue with bodily pain or mood swings, and 2.2% for cognitive problems.
Family Medicine/General Practice October 20th 2022
British Medical Journal (The BMJ)
A comprehensive review on the widespread uptake of vaping, including its origins and history, a timeline of discoveries, terminology, epidemiology, its use as a “harm reducer,” clinical presentations of vaping lung injuries (including an overview of the 2019 EVALI outbreak), the pathophysiology of vaping-induced lung injury, clinical aspects including outcomes, COVID-19 considerations, future directions, guidelines, and questions for future research.
Family Medicine/General Practice July 19th 2022